Lifevantage (LFVN) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lifevantage (LFVN) has outperformed MAIA Biotechnology (MAIA) over the past year, losing 34.9% versus a loss of 36.5%. Lifevantage is the larger company by market cap ($75.5 million vs $75.3 million), about 1.0 times the size. On valuation, MAIA Biotechnology trades at a lower forward P/E (1.1x vs 15.5x for Lifevantage).
Lifevantage pays a dividend yielding 3.08%, while MAIA Biotechnology does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LFVN | MAIA |
|---|---|---|
| Share price | $6.00 | $1.22 |
| Market cap | $75.54M | $75.33M |
| 1-day change | +0.17% | +6.09% |
| YTD return | -2.76% | -24.84% |
| 1-year return | -34.89% | -36.46% |
| 5-year return | -12.17% | — |
| P/E ratio (TTM) | 15.00 | — |
| Forward P/E | 15.52 | 1.10 |
| EPS (TTM) | $0.40 | $-0.62 |
| Dividend yield | 3.08% | 0.00% |
| Annual dividend | $0.185 | $0.00 |
| 52-week high | $11.71 | $3.19 |
| 52-week low | $3.90 | $0.87 |
| Distance from 52-week high | -48.76% | -61.76% |
| Analyst consensus | none | none |
| Avg. price target upside | +25.00% | +883.61% |
| Average volume | 59.73K | 527.89K |
| Shares outstanding | 12.59M | 61.74M |
| Employees | 209 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lifevantage offers a meaningfully higher dividend yield (3.08% vs 0.00%).
About Lifevantage
LFVN stock →LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Health Care · Biotechnology: Pharmaceutical Preparations · 209 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
LFVN vs MAIA FAQ
Which is bigger, Lifevantage or MAIA Biotechnology?
Lifevantage (LFVN) is larger, with a market capitalization of $75.54M compared with $75.33M for MAIA Biotechnology (MAIA).
Which stock has performed better over the past year, LFVN or MAIA?
LFVN returned -34.89% over the past 12 months, compared with -36.46% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Lifevantage or MAIA Biotechnology?
Lifevantage pays a dividend yielding 3.08%, while MAIA Biotechnology does not currently pay a regular dividend.
Are Lifevantage and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.